References
- Davies H , BignellGR, CoxCet al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002).
- Sinicrope FA , SmyrkTC, TougeronDet al. Mutation-specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas. Cancer 119(15), 2765–2770 (2013).
- Capper D , VoigtA, BozukovaGet al. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. Int. J. Cancer133(7), 1624–1630 (2013).
- Toon CW , ChouA, DesilvaKet al. BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer. Mod. Pathol. doi:10.1038/modpathol.2013.200 (2013) (Epub ahead of print).
- Hendriks YMC , de Jong AE, Morreau Het al. Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): a guide for clinicians. CA Cancer J. Clin.56(4), 213–225 (2006).
- Wheeler JM , LoukolaA, AaltonenLA, MortensenNJ, BodmerWF. The role of hypermethylation of the hMLH1 promoter region in HNPCC versus MSI+ sporadic colorectal cancers. J. Med. Genet.37(8), 588–592 (2000).
- Vasen HFA , BlancoI, Aktan-CollanKet al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 62(6), 812–823 (2013).
- Popat S , HubnerR, HoulstonRS. Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol.23(3), 609–618 (2005).
- Toon CW , WalshMD, ChouAet al. BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. Am. J. Surg. Pathol.37, 1592–1602 (2013).
- Domingo E , LaihoP, OllikainenMet al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J. Med. Genet.41(9), 664–668 (2004).
- Jensen LH , LindebjergJ, ByrielL, KolvraaS, CrügerDG. Strategy in clinical practice for classification of unselected colorectal tumours based on mismatch repair deficiency. Colorectal Dis.10(5), 490–497 (2008).
- Hampel H , FrankelWL, MartinEet al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J. Clin. Oncol. 26(35), 5783–5788 (2008).
- Shia J , StadlerZ, WeiserMRet al. Immunohistochemical staining for DNA mismatch repair proteins in intestinal tract carcinoma: how reliable are biopsy samples? Am. J. Surg. Pathol. 35(3), 447–454 (2011).
- Sargent DJ , MarsoniS, MongesGet al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J. Clin. Oncol. 28(20), 3219–3226 (2010).
- Sinicrope FA , FosterNR, ThibodeauSNet al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J. Natl. Cancer Inst. 103(11), 863–875 (2011).
- Douillard J-Y , Oliner KS, Siena Set al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med.369(11), 1023–1034 (2013).
- Loupakis F , CremoliniC, SalvatoreLet al. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur. J. Cancer doi:10.1016/j.ejca.2013.08.024 (2013) (Epub ahead of print).
Website
- NCCN Guidelines Version 3. 2012. Colon Cancer (2012). www.nccn.org/professionals/physician_gls/pdf/colon.pdf